Single dose of esketamine during surgery may ward off Post-Op depression in ovarian cancer patients
NCT ID NCT06624878
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether giving a low dose of esketamine during ovarian cancer surgery could prevent depressive symptoms that often follow. 568 women undergoing cytoreductive surgery received either esketamine or a placebo. Researchers measured depression using a standard questionnaire three days after surgery. The goal is to find a simple way to protect mental health during a difficult treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
esketamine
What this could lead to
If it works, this could offer a simple way to prevent depression after major cancer surgery, improving mental health and recovery.
What could go wrong
This is a single completed trial with a specific dose and timing. Results may not apply to other surgeries or populations, and the effect may be small or not lasting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Zhejiang cancer hospital
Hangzhou, Zhejiang, 310022, China